Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000865149> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2000865149 abstract "Background: XL765 is an oral, selective inhibitor of Class I PI3Ks, as well as TORC1 and TORC2. The PI3K pathway is frequently dysregulated in cancer cells and has been implicated as a mediator of resistance to EGFR inhibitors. In preclinical studies, XL765 has demonstrated dose‐dependent target modulation in tumor xenograft models. In an ongoing Phase 1 single agent clinical study, XL765 has exhibited robust pharmacodynamic activity in diverse solid tumors. Methods: Pts with advanced solid tumors are enrolled in successive cohorts of 3 to receive escalating doses of XL765 in combination with erlotinib. Cycles consist of 28 days of XL765 and erlotinib, each given qd. During the ongoing dose‐escalation phase of the study there is a 14‐day run‐in period of erlotinib monotherapy. Cycle 1 safety data determine dose limiting toxicities (DLTs). Tumor response is evaluated every 8 weeks. Results: As of 24Aug2009, 14 pts with advanced solid tumors have been enrolled: NSCLC (11), CRC (1), liposarcoma (1), and endometrial adenocarcinoma (1). Most of the NSCLC pts have been previously treated with erlotinib before entering the study. Pts have been treated at 2 dose levels of XL765 (30 and 50 mg) administered once‐daily in combination with 100 mg erlotinib. No DLTs or study treatment‐related SAEs have been reported. As of 03Aug2009, AEs have been reported for 7 pts. Grade 3 adverse events of nausea, vomiting, and anorexia considered related to study treatment were observed in one pt dosed at 30 mg qd. The PK of XL765 given in combination with erlotinib is consistent with that observed for XL765 given alone (Exelixis study XL765‐001). Likewise, XL765 does not appear to alter the PK of erlotinib. In skin biopsies, substantial post‐dose reductions were evident in phosphorylation of AKT, the mTOR substrate 4EBP1, and EGFR. For example, progressive pharmacodynamic effects were evident in serial skin biopsies from a pt with EGFR‐mutant NSCLC previously treated with erlotinib who has remained on study through 26 weeks, culminating in decreases in pAKT‐T308 (72%), p4EBP1 (57%), pERK (73%), and pEGFR (50%) at Day 85 post‐start of combination dosing (50 mg XL765/100 mg erlotinib). Pharmacodynamic analyses of paired tumor biopsies are in progress. Of the first 9 patients enrolled, five have remained on study for at least 12 weeks. Conclusions: XL765 in combination with erlotinib is generally well tolerated at doses up to 50 mg XL765/100 mg erlotinib, with no apparent drug‐drug PK interaction, and results in robust simultaneous inhibition of PI3K and EGFR signaling. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A254." @default.
- W2000865149 created "2016-06-24" @default.
- W2000865149 creator A5003842671 @default.
- W2000865149 creator A5013918150 @default.
- W2000865149 creator A5015582820 @default.
- W2000865149 creator A5040093136 @default.
- W2000865149 creator A5046729575 @default.
- W2000865149 creator A5048675362 @default.
- W2000865149 creator A5053391598 @default.
- W2000865149 creator A5056696568 @default.
- W2000865149 creator A5065431287 @default.
- W2000865149 creator A5085108777 @default.
- W2000865149 creator A5085336500 @default.
- W2000865149 creator A5090324173 @default.
- W2000865149 date "2009-12-10" @default.
- W2000865149 modified "2023-10-17" @default.
- W2000865149 title "Abstract A254: A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors" @default.
- W2000865149 doi "https://doi.org/10.1158/1535-7163.targ-09-a254" @default.
- W2000865149 hasPublicationYear "2009" @default.
- W2000865149 type Work @default.
- W2000865149 sameAs 2000865149 @default.
- W2000865149 citedByCount "2" @default.
- W2000865149 countsByYear W20008651492012 @default.
- W2000865149 crossrefType "proceedings-article" @default.
- W2000865149 hasAuthorship W2000865149A5003842671 @default.
- W2000865149 hasAuthorship W2000865149A5013918150 @default.
- W2000865149 hasAuthorship W2000865149A5015582820 @default.
- W2000865149 hasAuthorship W2000865149A5040093136 @default.
- W2000865149 hasAuthorship W2000865149A5046729575 @default.
- W2000865149 hasAuthorship W2000865149A5048675362 @default.
- W2000865149 hasAuthorship W2000865149A5053391598 @default.
- W2000865149 hasAuthorship W2000865149A5056696568 @default.
- W2000865149 hasAuthorship W2000865149A5065431287 @default.
- W2000865149 hasAuthorship W2000865149A5085108777 @default.
- W2000865149 hasAuthorship W2000865149A5085336500 @default.
- W2000865149 hasAuthorship W2000865149A5090324173 @default.
- W2000865149 hasConcept C111113717 @default.
- W2000865149 hasConcept C112705442 @default.
- W2000865149 hasConcept C121608353 @default.
- W2000865149 hasConcept C126322002 @default.
- W2000865149 hasConcept C143998085 @default.
- W2000865149 hasConcept C197934379 @default.
- W2000865149 hasConcept C2778087573 @default.
- W2000865149 hasConcept C2779438470 @default.
- W2000865149 hasConcept C2780580376 @default.
- W2000865149 hasConcept C31760486 @default.
- W2000865149 hasConcept C535046627 @default.
- W2000865149 hasConcept C71924100 @default.
- W2000865149 hasConcept C98274493 @default.
- W2000865149 hasConceptScore W2000865149C111113717 @default.
- W2000865149 hasConceptScore W2000865149C112705442 @default.
- W2000865149 hasConceptScore W2000865149C121608353 @default.
- W2000865149 hasConceptScore W2000865149C126322002 @default.
- W2000865149 hasConceptScore W2000865149C143998085 @default.
- W2000865149 hasConceptScore W2000865149C197934379 @default.
- W2000865149 hasConceptScore W2000865149C2778087573 @default.
- W2000865149 hasConceptScore W2000865149C2779438470 @default.
- W2000865149 hasConceptScore W2000865149C2780580376 @default.
- W2000865149 hasConceptScore W2000865149C31760486 @default.
- W2000865149 hasConceptScore W2000865149C535046627 @default.
- W2000865149 hasConceptScore W2000865149C71924100 @default.
- W2000865149 hasConceptScore W2000865149C98274493 @default.
- W2000865149 hasLocation W20008651491 @default.
- W2000865149 hasOpenAccess W2000865149 @default.
- W2000865149 hasPrimaryLocation W20008651491 @default.
- W2000865149 hasRelatedWork W1410407496 @default.
- W2000865149 hasRelatedWork W1596960575 @default.
- W2000865149 hasRelatedWork W1773110831 @default.
- W2000865149 hasRelatedWork W2058038208 @default.
- W2000865149 hasRelatedWork W2098809458 @default.
- W2000865149 hasRelatedWork W2111490539 @default.
- W2000865149 hasRelatedWork W2508076772 @default.
- W2000865149 hasRelatedWork W2513734563 @default.
- W2000865149 hasRelatedWork W2523212923 @default.
- W2000865149 hasRelatedWork W2565128857 @default.
- W2000865149 hasRelatedWork W2589932317 @default.
- W2000865149 hasRelatedWork W2600343292 @default.
- W2000865149 hasRelatedWork W2602667593 @default.
- W2000865149 hasRelatedWork W2607221480 @default.
- W2000865149 hasRelatedWork W2737025902 @default.
- W2000865149 hasRelatedWork W2739290122 @default.
- W2000865149 hasRelatedWork W2743115042 @default.
- W2000865149 hasRelatedWork W2747688417 @default.
- W2000865149 hasRelatedWork W3137082226 @default.
- W2000865149 hasRelatedWork W3214003785 @default.
- W2000865149 isParatext "false" @default.
- W2000865149 isRetracted "false" @default.
- W2000865149 magId "2000865149" @default.
- W2000865149 workType "article" @default.